Related Experiment Videos
Current treatment approaches for mantle-cell lymphoma
1Mayo Clinic, Stabile 628, 200 First St SW, Rochester, MN 55905, USA. Witzig@mayo.edu
Summary
Mantle Cell Lymphoma (MCL) is an aggressive B-cell cancer with poor prognosis. Novel agents show promise for relapsed MCL, but earlier integration is needed for durable responses.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Mantle Cell Lymphoma (MCL) is a distinct B-cell non-Hodgkin's lymphoma subtype.
- Patients typically present with advanced stage disease and have a median survival of 3-4 years.
- Current treatments offer short remissions, highlighting the need for novel therapeutic strategies.
Purpose of the Study:
- To review current treatment approaches for Mantle Cell Lymphoma.
- To discuss the efficacy of novel agents in relapsed MCL.
- To explore future directions for MCL treatment.
Main Methods:
- Review of existing literature on Mantle Cell Lymphoma treatment.
- Analysis of clinical trial data for novel agents in relapsed MCL.
- Discussion of treatment strategies based on patient eligibility for stem cell transplantation (SCT).
Main Results:
- Standard chemotherapy followed by SCT offers limited long-term benefit.
- Novel agents like bortezomib, temsirolimus, and thalidomide/rituximab show activity in relapsed MCL.
- Purine nucleoside analogues demonstrate efficacy as single agents or with rituximab.
Conclusions:
- Mantle Cell Lymphoma remains a challenging disease with unmet therapeutic needs.
- Novel agents demonstrate significant antitumor activity in relapsed settings.
- Integrating novel agents earlier and in combination may improve treatment outcomes for MCL patients.